Skip to main content

Caboxen 20 mg & 80 mg ( Cabozantinib)

Caboxen is presented as a cabozantinib medicine in 20 mg and 80 mg strengths. Cabozantinib is an oral targeted anticancer medicine classified as a tyrosine kinase inhibitor. It works by blocking selected proteins involved in cancer-cell signaling and tumor growth.

The stated active ingredient in Caboxen is cabozantinib. It is a multi-target tyrosine kinase inhibitor that acts on proteins such as MET, VEGF receptors, AXL, RET, and KIT.

Caboxen 20 mg is a stated strength of the product. Cabozantinib is used in selected cancer-treatment settings, depending on the formulation and regulatory approval. The correct use of Caboxen 20 mg must be determined from its confirmed product information and a healthcare professional's prescription.

Caboxen 80 mg is another stated product strength. The strength indicates the amount of active ingredient in an individual dosage unit, not necessarily the patient's daily dose. Its appropriate use depends on the confirmed formulation and prescribed treatment regimen.

Depending on the formulation and applicable approval, cabozantinib is used for certain cases of renal cell carcinoma, hepatocellular carcinoma, differentiated thyroid cancer, neuroendocrine tumors, and medullary thyroid cancer. Not every cabozantinib formulation is approved for all these conditions.

Caboxen's stated active ingredient, cabozantinib, blocks several receptor tyrosine kinases involved in cancer development. These include MET, VEGF receptors, and AXL. Blocking these pathways can interfere with tumor growth, cellular survival, and the formation of blood vessels that support tumors.

Cabozantinib is classified as a targeted anticancer medicine rather than a conventional cytotoxic chemotherapy drug. It belongs to the tyrosine kinase inhibitor class and works by interfering with selected molecular signaling pathways involved in cancer progression.

The exact dosage form of Caboxen must be confirmed from its packaging and product documentation. Cabozantinib reference products are available as both tablets and capsules. These formulations have different administration instructions and are not interchangeable.

Caboxen should be taken only according to the prescription and instructions for the confirmed product formulation. Patients should verify whether it is a capsule or tablet and follow the appropriate fasting and administration requirements.

Food instructions depend on the formulation. Reference cabozantinib tablets are generally taken at least one hour before or two hours after food. Reference capsules have a different fasting schedule. Patients must follow the instructions for their exact prescribed product.

A healthcare professional may reduce, interrupt, or discontinue cabozantinib when serious adverse reactions occur. Patients should never increase, reduce, or stop their treatment independently.

Commonly reported adverse reactions can include diarrhea, fatigue, nausea, decreased appetite, weight loss, high blood pressure, and hand-foot skin reactions. The frequency and severity vary according to the formulation, indication, and patient.

Serious risks include severe bleeding, blood clots, gastrointestinal perforation, fistula formation, severe hypertension, impaired wound healing, and osteonecrosis of the jaw. Patients should seek medical assessment if concerning symptoms develop.

Yes. Hypertension is an important potential adverse reaction associated with cabozantinib. Blood pressure should be assessed before and during treatment. Severe or uncontrolled hypertension requires medical attention.

Yes. Cabozantinib can interact with medicines that affect CYP3A4 metabolism. Strong CYP3A4 inhibitors may increase cabozantinib exposure, while strong inducers may decrease it. Patients should disclose all medicines, supplements, and herbal products to their healthcare professional.

Follow the missed-dose instructions for the exact prescribed product. Reference cabozantinib labels generally advise taking a missed dose if it can be taken within 12 hours of the scheduled time; otherwise, skip it and take the next dose at the usual time. Do not take an extra dose to compensate.

Cabozantinib can cause fetal harm and should not be used during pregnancy without an appropriate specialist assessment. Patients who could become pregnant should discuss effective contraception and pregnancy precautions with their healthcare professional.

Yes. Monitoring may include blood pressure, kidney function, liver function, urine protein, blood tests, and assessment for adverse reactions. The monitoring schedule depends on the patient's medical condition and treatment plan.

The two stated strengths are not automatically interchangeable. They contain different amounts of active ingredient per dosage unit. Any strength adjustment or change in the number of units must be determined by the prescribing healthcare professional.

Caboxen should only be prescribed by an appropriately qualified healthcare professional with experience in cancer treatment. The suitability of cabozantinib depends on the diagnosis, treatment history, product formulation, and individual medical condition.